APOB and coronary artery disorder: Our findings do not run contrary to these conclusions; rather, they shed light on whether the concentrations of cholesterol and/or triglycerides that are carried by apolipoprotein-B–containing lipoproteins contribute to risk of CHD beyond that encoded by apolipoprotein B. Based on these and recent data [15,26], the primary focus of lipid-modifying therapies ought to be the reduction in number of atherogenic lipoproteins (as measured by apolipoprotein B) rather than the reduction in cholesterol or triglycerides.